Explore the ongoing implementation of Nebraska's medical cannabis program as Nebraskans for Medical Marijuana hosts statewide town halls. Learn about ...
The White House's National Drug Control Strategy highlights concerns over high-potency marijuana and confirms the impending ...
New York's Office of Cannabis Management is now accepting applications for Cannabis Showcase Events, allowing licensed ...
Connecticut lawmakers reinstated THC caps on cannabis flower and concentrates, reversing an earlier plan. This cannabis ...
US Senators from both parties are reacting to the Trump administration's federal cannabis rescheduling proposal, highlighting ...
A new EU GMP Addendum from CSQ aims to help global cannabinoid producers meet European medical cannabis market standards, ...
Explore how the federal reclassification of medical cannabis to Schedule III is driving significant state-level regulatory ...
Medical cannabis rescheduling increases the need for clinician education. New courses offer vital, evidence-based guidance on ...
The U.S. House passed the Farm, Food, and National Security Act of 2026, establishing distinct regulatory frameworks for ...
The DEA has clarified HHC legality, classifying the synthetic cannabinoid hexahydrocannabinol as a Schedule I substance.
A new study on medical cannabis adverse events in Minnesota reveals that while infrequent, they can lead to treatment ...
Australian medical cannabis sales decreased 28.5% in H2 2025, the first significant drop since 2016. Discover how increased ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results